Treatment of Shiga Toxin-Producing Escherichia Coli (STEC) Infections
Supportive Care
- The primary treatment for STEC infections is supportive care with careful fluid management, while antimicrobial therapy should be avoided for STEC O157 and other STEC that produce Shiga toxin 2 due to increased risk of hemolytic uremic syndrome (HUS) 1, 2, 3
- Early and aggressive parenteral volume expansion is crucial in STEC infections to prevent complications, especially in patients at risk for HUS 1
- Reduced osmolarity oral rehydration solution (ORS) is recommended as first-line therapy for mild to moderate dehydration 1, 4
- For severe dehydration, shock, altered mental status, or failure of oral rehydration therapy, isotonic intravenous fluids such as lactated Ringer's or normal saline should be administered 4
Monitoring
- Close monitoring for development of HUS is essential, particularly in children under 5 years who are at highest risk 5, 6
- Monitor for thrombocytopenia, hemolytic anemia, and renal failure, which characterize HUS 5
Antimicrobial Therapy Considerations
- Antimicrobial therapy should be avoided in infections caused by STEC O157 and other STEC that produce Shiga toxin 2 1, 2, 3, 7
- Multiple retrospective studies have shown higher rates of HUS in patients treated with antimicrobials 2, 3
- In vitro data indicate that certain antimicrobial agents can increase Shiga toxin production 2, 3, 8
Special Populations
- For immunocompromised patients with severe illness and bloody diarrhea, empiric antibacterial treatment may be considered, but the risks of HUS development must be carefully weighed 1, 7
- Asymptomatic contacts of people with STEC infection should not receive antimicrobial therapy 1, 7
Adjunctive Therapies
- Antimotility agents should not be used in suspected or documented STEC infections as they may increase the risk of HUS 2, 3
Prevention of Complications
- Prompt and accurate diagnosis is crucial for appropriate management and prevention of complications 5, 6